Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Jang, T. W. [1 ]
Kim, T. [2 ]
机构：
[1] Kosin Univ Gospel Hosp, Busan, South Korea
[2] Armed Forces Goyang Hosp, Goyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Afatinib; osimertinib; real-world effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-27
引用
收藏
页码：S651 / S651
页数：1
相关论文
共 50 条
  • [21] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [22] Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
    Araki, Taisuke
    Kanda, Shintaro
    Komatsu, Masamichi
    Sonehara, Kei
    Tateishi, Kazunari
    Takada, Munetake
    Kato, Akane
    Yamamoto, Manabu
    Nishie, Kenichi
    Hama, Mineyuki
    Agatsuma, Toshihiko
    Kakizaki, Yumiko
    Yoshiike, Fumiaki
    Matsuo, Akemi
    Chiaki, Tomoshige
    Samizo, Kanae
    Takagi, Yoshiko
    Yamaura, Maki
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1320 - 1327
  • [23] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2019, 15 (25) : 2905 - 2913
  • [24] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [25] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 917 - 926
  • [26] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
  • [27] Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Hoang, T. T. A.
    Nguyen, T. T. T.
    Pham, C. T. M.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S626 - S627
  • [28] Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [29] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Inomata, Minehiko
    Matsumoto, Masahiro
    Mizushima, Isami
    Hayashi, Kana
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Tobe, Kazuyuki
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2022, 16 (01)
  • [30] Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review
    Nargesi, Shahin
    Dolatshahi, Zeinab
    Rezapour, Aziz
    Alipour, Vahid
    Souresrafil, Aghdas
    Farabi, Hiro
    Javadmoosavi, Seyed Arash
    Safakhah, Mandana
    Moradi, Najmeh
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 543 - 554
12345